Test Id : KCSFP
Immunoglobulin Kappa Free Light Chain, Spinal Fluid (Non-Orderable)
Useful For
Suggests clinical disorders or settings where the test may be helpful
Only orderable as part of a profile. For more information see MSP3 / Multiple Sclerosis (MS) Cascade, Serum and Spinal Fluid.
Diagnosis of multiple sclerosis and other demyelinating conditions
Method Name
A short description of the method used to perform the test
Only orderable as part of a profile. For more information see MSP3 / Multiple Sclerosis (MS) Cascade, Serum and Spinal Fluid.
Nephelometry
NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test
Aliases
Lists additional common names for a test, as an aid in searching
Cerebrospinal fluid Free Light Chain
Free Light Chain, cerebrospinal fluid
Free Light Chain, spinal fluid
Multiple Sclerosis (MS)
Oligoclonal Banding
Spinal fluid Free Light Chain
Specimen Type
Describes the specimen type validated for testing
CSF
Ordering Guidance
For evaluation of multiple sclerosis, the following are also available as individually orderable tests:
SFIG / Cerebrospinal Fluid IgG Index Profile, Serum and Spinal Fluid
OLIG / Oligoclonal Banding, Serum and Spinal Fluid
Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing
Only orderable as part of a profile. For more information see MSP3 / Multiple Sclerosis (MS) Cascade, Serum and Spinal Fluid.
Specimen Type: Spinal fluid (CSF)
Container/Tube: Sterile vial
Specimen Volume: 1 mL
Collection Instructions:
1. Submit CSF from collection vial number 4 (preferred); vial number 1, 3, and 2 are also acceptable (in this order).
2. Label specimen as CSF.
Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the testing laboratory. The minimum volume is sufficient for one attempt at testing.
0.5 mL
Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected
| Gross hemolysis | Reject |
| Gross icterus | OK |
Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| CSF | Frozen (preferred) | 28 days | |
| Ambient | 24 hours | ||
| Refrigerated | 72 hours |
Useful For
Suggests clinical disorders or settings where the test may be helpful
Only orderable as part of a profile. For more information see MSP3 / Multiple Sclerosis (MS) Cascade, Serum and Spinal Fluid.
Diagnosis of multiple sclerosis and other demyelinating conditions
Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system. The clinical diagnosis of MS is centered on each individual patient while applying diagnostic guidelines. Immunoglobulin free light chain (FLC) presence in cerebrospinal fluid (CSF) is an alternative for diagnosis of MS using nephelometry. Light chains are produced in excess during antibody formation and secreted from the plasma cells or plasmablasts. Quantitative FLC assays use antisera directed against epitopes that are exposed only when the light chains are free (unbound to heavy chain) in solution. FLC immunoassays can be used to specifically quantitate FLC even in the presence of large concentrations of polyclonal immunoglobulins. This assay measures kappa FLC (kFLC) concentration directly in CSF by nephelometry and does not require a paired serum specimen.
Cerebrospinal fluid kFLC concentration and the kFLC index are related but distinct measurements. Direct CSF kFLC concentration may reflect both intrathecal kFLC production and kFLC entering the CSF from the circulation. The kFLC index additionally incorporates serum kFLC and paired CSF and serum albumin measurements to account for systemic kFLC concentration and blood-CSF barrier permeability.
The 2024 McDonald criteria recognize the kFLC index as an alternative to CSF-restricted oligoclonal bands (OCBs) for demonstrating intrathecal immunoglobulin synthesis.(1) The CSF kFLC concentration on its own is not the kFLC measure specified in these criteria. Nevertheless, direct CSF kFLC measurement provides a rapid, automated, quantitative approach that may support evaluation for MS and can be used as part of a reflex testing strategy.
Oligoclonal band testing uses isoelectric focusing with IgG-specific detection of paired CSF and serum to identify CSF-restricted IgG bands. OCB testing is an established method for demonstrating intrathecal immunoglobulin synthesis but requires specialized testing and visual interpretation.
Neither an increased CSF kFLC concentration, an increased kFLC index, nor CSF-restricted OCBs are specific for MS. Abnormal results may occur in other inflammatory, infectious, autoimmune, malignant, or neurologic disorders and should be interpreted together with the clinical presentation and imaging findings.
This profile combines the ease of use and interpretation of the quantitative measurement of kappa-free light chains in CSF and allies it to the traditional interpretation of oligoclonal bands for optimized efficiency in laboratory testing for demyelinating diseases and improved test utilization.
Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Only orderable as part of a profile. For more information see MSP3 / Multiple Sclerosis (MS) Cascade, Serum and Spinal Fluid.
Medical decision point: 0.1000 mg/dL
Positive: > or =0.1000 mg/dL
Borderline: 0.0600 mg/dL-0.0999 mg/dL
Negative: <0.0600 mg/dL
Interpretation
Provides information to assist in interpretation of the test results
Cerebrospinal fluid (CSF) kappa free light chain (kFLC) concentration is a quantitative marker of immunoglobulin production within the central nervous system but may also be influenced by circulating kFLC concentration and blood-CSF barrier permeability.
Results are interpreted as:
Negative: <0.0600 mg/dL
Borderline: 0.0600 to <0.1000 mg/dL
Positive: > or =0.1000 mg/dL
An increased CSF kFLC concentration is not specific for multiple sclerosis (MS) and may occur in other inflammatory, infectious, autoimmune, malignant, and neurologic disorders. Clinical and radiologic correlation is recommended.
Standalone CSF kFLC concentration should not be confused with the kFLC index. The kFLC index incorporates paired CSF and serum kFLC and albumin measurements and is the kFLC-based approach recommended for demonstrating positive CSF in the 2024 McDonald criteria.(1)
The 2024 McDonald criteria recognize intrathecal kFLC synthesis as an alternative to CSF-restricted oligoclonal bands for demonstrating a positive CSF result.(1) The recommended approach is calculation of the kFLC index:
kFLC index = (CSF kFLC / serum kFLC) / (CSF albumin / serum albumin)
The calculation requires paired CSF and serum kFLC and albumin measurements. A kFLC index greater than or equal to 6.1 is the recommended threshold for positive CSF when validated assays are used.
Mayo Clinic Laboratories provides the Kappa Index Calculator to facilitate calculation of the index and determine whether the result meets the greater than or equal to 6.1 threshold. A positive kFLC index supports intrathecal immunoglobulin synthesis but is not specific for MS and should be interpreted with clinical and imaging findings.
Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
No significant cautionary statements
Supportive Data
Initial Mayo Clinic studies evaluated direct cerebrospinal fluid (CSF) kappa free light chain (kFLC) concentration as a quantitative alternative to CSF-restricted oligoclonal band (OCB) testing in patients undergoing evaluation for multiple sclerosis (MS) and other demyelinating diseases.(2)
A subsequent Mayo Clinic study evaluated 702 retrospective and 657 prospective paired CSF and serum specimens submitted for OCB testing. The retrospective cohort established a CSF kFLC concentration of 0.1000 mg/dL as the medical decision point, which was then independently evaluated in the prospective cohort. In the prospective cohort, sensitivity for MS was 78.6% for both CSF kFLC concentration and OCB testing. Specificity was 87.1% for CSF kFLC concentration and 89.4% for OCB testing; these differences were not statistically significant.(3) These findings supported direct CSF kFLC concentration as a rapid, quantitative approach that does not require a paired serum specimen.
The 2024 revisions to the McDonald criteria subsequently incorporated intrathecal kFLC synthesis as an alternative to CSF-restricted OCBs for establishing positive CSF.(1) The accompanying recommendations specify calculation of the kFLC index, which incorporates paired CSF and serum kFLC and albumin measurements, with an index of 6.1 or greater recommended as the decision threshold,(4,5)
Therefore, direct CSF kFLC concentration remains useful as a quantitative CSF biomarker and as a component of reflex testing strategies, whereas the kFLC index is the kFLC-based measurement specifically recommended for establishing positive CSF under the 2024 McDonald criteria.(1)
Clinical Reference
Recommendations for in-depth reading of a clinical nature
1. Montalban X, Lebrun-Frenay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24(10):850-865. doi:10.1016/S1474-4422(25)00270-4
2. Gurtner KM, Shosha E, Bryant SC, et al. CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. Clin Chem Lab Med. 2018;56(7):1071-1080
3. Saadeh RS, Bryant SC, McKeon A, et al. CSF kappa free light chains: Cutoff validation for diagnosing multiple sclerosis. Mayo Clin Proc. 2022;97(4):738-751. doi:10.1016/j.mayocp.2021.09.014
4. Deisenhammer F, Hegen H, Arrambide G, et al. Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis. EBioMedicine. 2025;120:105905. doi:10.1016/j.ebiom.2025.105905
5. Hegen H, Walde J, Berek K, et al. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis. Mult Scler. 2023;29(2):169-181. doi:10.1177/13524585221134213
Method Description
Describes how the test is performed and provides a method-specific reference
In this nephelometric method, the light scattered by the antigen-antibody complexes is measured. The intensity of the measured scattered light is proportional to the amount of antigen-antibody complexes in the sample under certain conditions.
Antigen-antibody complexes are formed when a sample containing antigen and the corresponding antiserum are put into a cuvette. A light beam is generated with a light emitting diode (LED), which is transmitted through the cuvette. The light is scattered by the immuno-complexes that are present. An antigen-antibody complex is formed in the final measurement.
The result is calculated by subtracting the value of the final measurement from the initial measurement. The distribution of intensity of the scattered light depends on the ratio of the particle size of the antigen-antibody complexes to the radiated wavelength.(Instruction manual: Siemens Nephelometer II, Siemens, Inc, 07/2019)
PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information
Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.
Monday through Friday
Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.
Performing Laboratory Location
Indicates the location of the laboratory that performs the test
Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact Customer Service.
Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
CPT codes are provided by the performing laboratory.
CPT codes are provided by the performing laboratory.
83521
LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.
| Test Id | Test Order Name | Order LOINC Value |
|---|---|---|
| KCSFP | Kappa Free Light Chain, CSF | 48774-4 |
| Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
|---|---|---|
| KCSFP | Kappa Free Light Chain, CSF | 48774-4 |